CAS: 1353550-13-6; Olmutinib

上下游产品

4-(3-氨基苯氧基)-N-(4-(4-甲基哌嗪-1-基)苯基)噻吩并[3,2-D]嘧啶-2-胺 4-(3-Aminophenoxy)-N-(4-(4-Methylpiperazine-1-yl)Phenyl)Thieno[3,2-D]Pyrimidine-2-Amine 1353553-09-9

2-(Methanesulfonyl)Thieno[3,2-D]Pyrimidin-4(3H)-One置于potassium Carbonate,三氟乙酸,三氯氧磷体系中,用 水,乙腈 用作溶剂,化学反应 8.0H,反应生成奥莫替尼
参考文献: Novel Method For Preparing Thienopyrimidine Compound And Intermediates Used Therein[fr] Nouveau Procédé De Préparation D'Un Composé De Thiénopyrimidine Et Intermédiaires Utilisés Dans Ce Procédé
标题: Novel Method For Preparing Thienopyrimidine Compound And Intermediates Used Therein[fr] Nouveau Procédé De Préparation D'Un Composé De Thiénopyrimidine Et Intermédiaires Utilisés Dans Ce Procédé
摘要:本发明提供了一种新颖的制备formula 1的噻吩嘧啶化合物的方法,该化合物是一种选择性抑制酪氨酸激酶活性的药物,特别是对突变表皮生长因子受体酪氨酸激酶的抑制作用,以及该方法中使用的新颖中间体.

专利信息

专利号:US-2022233673-A1
优先权日:2019-06-04
标 题:METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STxB) MONOMERS AND OLIGOMERS, AND USES THEREOF
发明人：BILLET ANNE; SCHMIDT FRÉDÉRIC; JOHANNES LUDGER; SERVENT DENIS; MOURIER GILLES; TARTOUR ÉRIC; KAY MICHAEL; FULCHER JAMES M
权利人:INST CURIE; CENTRE NAT RECH SCIENT; INST NAT SANTE RECH MED; COMMISSARIAT A LENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES CEA; APHP ASSIST PUBLIQUE HOPITAUX DE PARIS; UNIV PARIS; UNIV OF UTAH RESEARCH FOUDATION; UNIV UTAH RES FOUND
摘要:A method of producing a monomer of a Shiga toxin B-subunit (STxB) protein or of a variant thereof by peptide chemical synthesis, as well as to a method of producing a pentamer of the STxB protein or of the variant thereof. The methods are particularly advantageous as they overcome major issues typically observed in peptide chemical synthesis, including solubility and purity issues.

专利号:US-2025289827-A1
优先权日:2022-12-02
标 题:Morphic forms of a mutant braf degrader and methods of manufacture thereof
发明人：YU ROBERT T; HE MINSHENG; SCHNADERBECK MATTHEW J; KREGER BRIDGET; POLLOCK ROY MACFARLANE; JIANG SIYI; LI MEIQI; CHEN BOLU; LU JIANNAN
权利人:C4 THERAPEUTICS INC
摘要:Advantageous isolated morphic forms of (3R)-3-[6-[2-cyano-3-[[ethyl(methyl)sulfamoyl]amino]-6-fluorophenoxy]-4-oxoquinazolin-3-yl]-8-[2-[1-[3-(2,4-dioxo-1,3-diazinan-1-yl)-5-fluoro-1-methylindazol-6-yl]-4-hydroxypiperidin-4-yl]acetyl]-1-oxa-8-azaspiro[4.5]decane (Compound 1), which is a mutant BRAF degrader, and methods to prepare Compound 1 morphic forms for therapeutic applications are provided in the invention. The invention also provides improved methods for the synthesis of Compound 1, new pharmaceutical compositions comprising Compound 1, and new uses of Compound 1.

专利号:US-12390420-B1
优先权日:2024-10-22
标题 :Compositions for targeted delivery of therapeutic agents and methods for the synthesis and use thereof
发明人：EGUCHI MASAKATSU
权利人:BRYET US INC
摘要:The present disclosure provides compositions and methods for delivering therapeutic agents to particular tissues or cells in a subject. The composition disclosed herein combines unique properties of porous micro- or nano-particles with host-guest chemistry provided by functionalized silicon particle, offering a versatile approach to addressing the challenges associated with delivering therapeutic agents to target tissues or sites within the body. The present disclosure also provides a method for synthesizing a composition capable of delivering therapeutic agents to particular tissues or cells in a subject.